Will interferon-free regimens prevail?
Will interferon-free regimens prevail?
复制标题
无干扰素治疗方案会流行吗？
作者：
C. Welsch;S. Zeuzem
许多有前景的针对丙型肝炎病毒（HCV）蛋白的小分子抑制剂（定向抗病毒药物[DAA]）和靶向宿主细胞因子的化合物（宿主靶向药物[hta]）目前正处于药物开发和临床试验阶段，而基于聚乙二醇干扰素（Peg-IFN）的治疗方法的禁禁症和不良反应限制了其临床适用性。越来越多的替代治疗方案正在推动对节省干扰素方案的研究，并为干扰素在HCV治疗中的未来地位问题铺平道路。美国食品和药物管理局（fda）和欧洲药品管理局（ema）最近批准了2种daa，开启了慢性丙型肝炎病毒感染（CHC）治疗的新时代。新的护理标准是三联治疗，将先前的标准，1 Peg-IFN- +利巴韦林（RBV）与酮酰胺蛋白酶抑制剂相结合。新的护理标准被批准用于感染基因型1型HCV的患者，这是欧洲和北美最流行的基因型。酮酰胺化合物boceprevir （Victrelis, Merck & Co, Whitehouse Station， NJ）和telaprevir （Incivek, Vertex Pharmaceuticals, Cambridge， MA）被设计用于模拟基因型1的天然NS3/4A蛋白酶底物
Many promising small molecule inhibitors directed against hepatitis C virus (HCV) proteins (directacting antiviral [DAA] agents) and compounds targeting host cell factors (host-targeting agents [HTAs]) are currently in the drug development and clinical trial pipeline, whereas contraindications and adverse effects limit the clinical applicability of peginterferon (Peg-IFN)-based therapies. The increasing number of alternative treatment options is driving the investigation of interferon-sparing regimens and paving the way for the question on the future place for interferon in HCV therapy. The recent approval of 2 DAAs by the US Food and Drug Administration and European Medicines Agency has opened a new era in the treatment of chronic HCV infection (CHC). The new standard of care is a triple therapy, combining the previous standard, 1 Peg-IFN- plus ribavirin (RBV), with a ketoamide protease inhibitor. The new standard of care is licensed for patients infected with genotype 1 HCV, the most prevalent genotype in Europe and North America. Ketoamide compounds, boceprevir (Victrelis, Merck & Co, Whitehouse Station, NJ) and telaprevir (Incivek, Vertex Pharmaceuticals, Cambridge, MA), are designed to mimic the natural NS3/4A protease substrate in genotype 1
影响因子：
158.5
作者：
Fried, MW;Shiffman, ML;Yu, J
通讯作者：
Yu, J